Dialysis Infection Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global dialysis infection treatment market size is likely to be valued at US$3.5 billion in 2026 and is estimated to reach US$6.6 billion by 2033, growing at a CAGR of 9.6% during the forecast period from 2026 to 2033, driven by the rising use of catheter-based dialysis access and the resulting need to prevent bloodstream infections.

Surging numbers of patients with diabetes, hypertension, and advanced kidney disease are expanding the population requiring long-term dialysis care.

Driver - Rising Catheter Use to Propel Demand for Infection Management

The continued use of central venous catheters in hemodialysis creates a key driver for the market for dialysis infection treatment products. Catheters have a much higher infection risk than fistulas and grafts. The CDC's latest dialysis surveillance data for 2025 recorded 12,718 bloodstream infection events among dialysis patients. The infection rate was 0.62 per 100 access-months for central venous catheters, compared with only 0.10 for fistulas.

Catheters also accounted for a much higher rate of intravenous antibiotic starts and signs of local infection. This risk is difficult to eliminate as some patients require catheters when an arteriovenous fistula or graft is not yet ready, cannot be created, or has failed. The 2025 USRDS report shows that 16% of people progressing to ESKD started hemodialysis with a catheter, while only 3% started with an arteriovenous access in the reported cohort. This supports demand for antimicrobial catheter locks, catheter-care products, antibiotics, and other infection-control technologies.

A Large Long-term Dialysis Population to Expand Infection Exposure

The growing number of people requiring long-term kidney replacement therapy is another important demand driver. Patients receiving dialysis undergo repeated vascular access or catheter manipulation over long periods. Each additional month of treatment creates further exposure to infection risks. In the U.S., CDC estimates that approximately 500,000 people receive maintenance hemodialysis, giving infection-treatment providers a large recurring patient base.

The underlying disease burden is also important. Diabetes and hypertension are major contributors to kidney failure, while aging populations increase the number of patients requiring renal replacement therapy. The 2025 USRDS report recorded 675,065 U.S. patients receiving dialysis in 2023, including 588,613 on hemodialysis and 84,669 on peritoneal dialysis.

Restraint - Serious Cardiovascular Complications May Limit Treatment Outcomes

Dialysis infections can become more difficult to manage when they spread beyond the catheter or bloodstream. CRBSI can progress to sepsis and infective endocarditis, especially when Staphylococcus aureus is involved. A 2026 study of hospitalized catheter-dependent hemodialysis patients with CRBSI found that Gram-positive organisms represented 70.6% of cases and S. aureus accounted for 35.3%.

The wider cardiovascular burden also complicates treatment. The 2025 USRDS report found that cardiovascular causes accounted for 41.3% of deaths among U.S. hemodialysis patients in 2023, while septicemia accounted for another 4.4%. Severe infections can hence increase hospitalization, treatment complexity, and mortality risks. These outcomes can also make physicians more cautious about prolonged catheter use and repeated invasive procedures.

Opportunity - Targeted Catheter-lock Products to Prevent Infections before They Spread

One of the strongest opportunities is the development and adoption of antimicrobial catheter-lock solutions. These products are designed to remain inside the catheter between dialysis sessions and target microorganisms before they enter the bloodstream. The approach is particularly attractive as it can potentially reduce infection without immediately removing a patient's vascular access. DefenCath provides a strong commercial example.

The FDA approved the taurolidine-heparin catheter-lock solution for reducing CRBSIs in adults receiving chronic hemodialysis through a central venous catheter. In its pivotal study, the product reduced CRBSI risk by 71% compared with heparin alone. The opportunity is not limited to taurolidine-based products. Research into antibiotic-lock combinations is continuing, while recent evidence supports the effectiveness of localized catheter treatment. A 2025 meta-analysis covering 17 studies and 3,482 hemodialysis catheters reported a 63% reduction in CRBSIs with antibiotic-lock therapy. This supports further development of catheter-specific antimicrobial technologies.

Antimicrobial Dressings and Infection-control Bundles to Broaden the Market

Another opportunity lies in products that prevent infection around the catheter rather than treating bloodstream infection after it occurs. These include antimicrobial dressings, disinfecting caps, antiseptic solutions, catheter-care kits, and standardized infection-control bundles. Recent research is supporting this direction. A 2026 randomized trial from West China Hospital evaluated glucose-chlorhexidine antimicrobial dressings in patients receiving continuous renal replacement therapy.

Local catheter-site infections occurred less frequently in the antimicrobial-dressing group, while CRBSIs were also lower. This indicates that infection prevention can become an important product category alongside antibiotics and catheter locks. The opportunity is relevant in emerging markets, where improvements in dialysis-unit practices can have a meaningful impact. A 2025 Indian interventional study evaluated education and a bundled infection-control approach in a dialysis unit, showing that structured infection-control programs are being actively studied in the country.

Infection Type Insights

Catheter-Related Bloodstream Infections (CRBSIs) are predicted to lead with a share of about 34.7% in 2026, as central venous catheters create a direct pathway for microorganisms to enter the bloodstream, while repeated access during hemodialysis provides frequent opportunities for contamination and catheter colonization. The CDC identifies central venous catheters as the dialysis access type with the highest infection risks. The clinical burden is also substantial. CDC reported more than 14,000 bloodstream infections among U.S. dialysis patients in 2020, with more than one-third caused by Staphylococcus aureus. CDC also notes that vascular-access type is a major determinant of infection risk.

Peritonitis is estimated to be the fastest-growing type over the forecast period, as it is closely linked to the expanding use and continued adoption of peritoneal dialysis. Unlike hemodialysis, PD requires repeated handling of an abdominal catheter and connection systems. A break in aseptic technique can introduce microorganisms directly into the peritoneal cavity. Fresenius Medical Care specifically highlights hand hygiene, exit-site care, masks, workspace preparation, and correct bag exchanges as important measures for preventing PD peritonitis.

Treatment Type Insights

Antibiotics are anticipated to dominate with a share of around 32.8% in 2026, as bacterial organisms cause most dialysis-associated bloodstream and catheter infections, particularly infections involving Staphylococcus aureus and other Gram-positive organisms. CDC identifies S. aureus as the most common cause of dialysis bloodstream infections in the U.S. Antibiotics are also embedded in established treatment protocols. The ISPD guideline provides detailed recommendations for empirical and organism-specific antibiotic therapy in PD peritonitis.

Antifungals are expected to be the fastest-growing application over the forecast period, as fungal dialysis infections are difficult to treat and frequently require catheter removal. A 2025 nationwide study found that Candida accounted for 82.5% of fungal peritonitis cases, while fluconazole was used in 80% of patients. Recent evidence also shows a connection between repeated antibiotic exposure and fungal peritonitis. In the same 2025 study, 62.5% of patients had received two or more antibiotics during the preceding three months, and multiple antibiotic exposure was independently associated with fungal peritonitis.

North America Dialysis Infection Treatment Market Trends

North America is predicted to dominate in 2026 globally with a share of approximately 40.3%, as it combines a large dialysis population with mature infection surveillance, established reimbursement systems, and rapid adoption of specialized infection-prevention technologies. The region further has a strong commercial environment for specialized products. DefenCath's FDA approval is an important example as it created a specifically indicated product for reducing CRBSIs in chronic hemodialysis patients using central venous catheters. The product's clinical evidence showed a 71% reduction in CRBSI risk.

U.S. Dialysis Infection Treatment Market Trends

A share of nearly 67.3% is expected to be held by the U.S. in 2026 in North America, owing to its large dialysis population, high healthcare spending, detailed infection surveillance, and increasing use of products designed specifically to prevent catheter infections. The U.S. had 675,065 patients receiving dialysis in 2023, according to the 2025 USRDS report. Hemodialysis accounted for 588,613 patients, making catheter and vascular-access infection management particularly important.

Asia Pacific Dialysis Infection Treatment Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026 with a share of around 24.4%, as dialysis capacity is expanding across large populations while access to renal-care services and infection-control infrastructure continues to improve. The region has a particularly large addressable patient population. China and India together account for a substantial share of the world's population and have rapidly expanding chronic kidney disease burdens. As more patients progress to kidney failure, the number requiring long-term dialysis increases.

China Dialysis Infection Treatment Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 33.5%, as the number of patients receiving dialysis has increased substantially, with hemodialysis accounting for most treatment and creating a large vascular-access management requirement. A national analysis of Chinese insurance claims found that the standardized prevalence of dialysis increased from 255.11 patients per million in 2013 to 419.39 per million in 2017. The study projected dialysis prevalence to reach 629.67 per million by 2025, equivalent to about 874,000 patients.

India Dialysis Infection Treatment Market Trends

In 2026, India is projected to account for a share of just about 20.4% in Asia Pacific, as its dialysis population is expanding while catheter dependence, infection-control gaps, and the need for affordable infection-prevention solutions remain significant. The country has a particularly strong opportunity for catheter infection products as vascular-access practices vary widely across facilities. A 2025 prospective study from Gauhati Medical College evaluated 67 hemodialysis patients with suspected CRBSIs and specifically identified prolonged catheter use and variations in infection-control practices as important concerns.

Europe Dialysis Infection Treatment Market Trends

Europe will likely see steady growth over the forecast period with a share of roughly 19.5% in 2026 globally, as it has a large and aging dialysis population, established renal registries, standardized clinical practices, and strong emphasis on infection prevention and treatment quality. The European Renal Association's registry collects kidney replacement therapy data through national and regional renal registries across Europe and neighboring countries. Its 2023 Annual Report was published in November 2025, with the accompanying clinical summary published in Clinical Kidney Journal in February 2026.

Germany Dialysis Infection Treatment Market Trends

Germany is predicted to register a substantial share of approximately 32.6% in 2026 in Europe, supported by a large renal replacement therapy population and demographic aging. A 2025 clinical review estimated that around 80,000 people in Germany depend on permanent renal replacement therapy. The authors expect prevalence to continue increasing owing to demographic developments and longer life expectancy.

U.K. Dialysis Infection Treatment Market Trends

A share of nearly 26.6% is predicted to be held by the U.K. in 2026 in Europe, as its mature renal-care system is supported by national data collection, standardized clinical monitoring, and continued demand for safer dialysis access. The U.K. Renal Registry has historically collected detailed information from renal centers across the country. Its reporting covers in-center hemodialysis, peritoneal dialysis, home hemodialysis, and transplantation. Earlier registry reporting covered approximately 70,000 patients receiving renal replacement therapy across U.K. centers.

The global dialysis infection treatment market is moderately fragmented, with a few specialized players gaining influence alongside large dialysis, medical-device, and pharmaceutical companies. The market is not controlled by one drug category. Competition spans antimicrobial catheter-lock solutions, antibiotics, antifungals, catheter-care products, antimicrobial caps, and infection-prevention systems. CorMedix has a particularly differentiated position through DefenCath (taurolidine and heparin), which is specifically approved by the U.S. FDA to reduce CRBSIs in adults receiving chronic hemodialysis through a central venous catheter.

Large dialysis providers such as Fresenius Medical Care and DaVita influence the market as they operate extensive treatment networks and can drive adoption of infection-control protocols and products. Medical-device companies such as B. Braun, Baxter, Nipro, BD, Medtronic, and ICU Medical compete through vascular-access products, catheter systems, antimicrobial technologies, and dialysis infrastructure. Pharmaceutical companies participate mainly through antibiotics and antifungals rather than dialysis-specific products. The competitive direction is shifting from treating infection after it occurs toward preventing catheter colonization and bloodstream infection earlier.

Key Industry Developments

• In July 2026, researchers at West China Hospital and Sichuan University published a randomized controlled trial evaluating glucose-chlorhexidine antimicrobial dressings in patients receiving continuous renal replacement therapy. Among 410 participants, local catheter-site infections occurred in 15.6% of the antimicrobial-dressing group versus 40.0% with sterile dressings, while CRBSI rates were 6.3% versus 13.7%. The study adds evidence for antimicrobial dressings as another prevention tool around dialysis catheters.
• In December 2025, CorMedix reported interim real-world evidence showing that DefenCath was associated with a 72% reduction in CRBSIs and a 70% reduction in hospitalizations related to CRBSIs. The study was conducted with U.S. Renal Care among adult hemodialysis patients using central venous catheters. The findings provided additional real-world evidence following DefenCath's commercial launch in the U.S.
• In August 2025, CorMedix announced an agreement to acquire Melinta Therapeutics for US$300 million in upfront consideration, comprising US$260 million in cash and US$40 million in CorMedix equity. The transaction added several anti-infective products, including REZZAYO, MINOCIN, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, expanding CorMedix's infectious-disease portfolio beyond DefenCath. The companies also agreed to a potential additional regulatory milestone of up to US$25 million.